Related Experiment Videos
Silent neuropathy in leprosy: an epidemiological description
1Green Pastures Hospital, Pokhara, Nepal.
Leprosy Review
|December 1, 1994
Summary
Silent Neuropathy (SN) affects leprosy patients, often appearing early in treatment. Early nerve function assessment is crucial for detecting and preventing permanent nerve damage in leprosy patients.
Area of Science:
- Neurology
- Epidemiology
- Infectious Diseases
Background:
- Leprosy can cause nerve damage, often presenting with sensory or motor impairment.
- Silent Neuropathy (SN) is a proposed term for nerve dysfunction in leprosy without typical reaction signs.
- Understanding SN's epidemiology and risk factors is vital for early detection and management.
Purpose of the Study:
- To present epidemiological data on Silent Neuropathy (SN) in leprosy patients.
- To define and characterize SN based on clinical and functional assessments.
- To identify risk factors and potential aetiologies for SN in leprosy.
Main Methods:
- Retrospective study of 536 leprosy patients at Green Pastures Hospital, Nepal.
- Nylon filament testing for touch thresholds and manual muscle testing for nerve function assessment.
- Analysis of incidence, timing, and risk factors for SN development.
Main Results:
- Almost 7% of new patients presented with SN; incidence was 4.1 per 100 person-years.
- 75% of SN episodes occurred within the first year of chemotherapy.
- Steroid treatment significantly improved nerve function in affected nerves over 3 months.
- Extensive disease and specific clinical signs indicated increased risk for SN.
Conclusions:
- Silent Neuropathy (SN) is a distinct clinical entity in leprosy, requiring specific diagnostic criteria.
- Early and regular nerve function assessment is essential for detecting SN and preventing disability.
- Further research into SN aetiologies, including Schwann cell pathology and immune reactions, is warranted.